Evotaz

RSS

atazanavir / cobicistat

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Evotaz. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Evotaz.

For practical information about using Evotaz, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 29/04/2020

Authorisation details

Product details
Name
Evotaz
Agency product number
EMEA/H/C/003904
Active substance
  • cobicistat
  • atazanavir sulfate
International non-proprietary name (INN) or common name
  • atazanavir
  • cobicistat
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
J05AR
Publication details
Marketing-authorisation holder
Bristol-Myers Squibb Pharma EEIG
Revision
10
Date of issue of marketing authorisation valid throughout the European Union
13/07/2015
Contact address

Plaza 254
Blanchardstown Corporate Park 2
Dublin 15
D15 T867
Ireland

Product information

17/04/2020 Evotaz - EMEA/H/C/003904 - IG/1223/G

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir.

Assessment history

Related content

How useful was this page?

Add your rating